These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33276986)

  • 1. Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis.
    Travaglino A; Raffone A; Gencarelli A; Saracinelli S; Riccardi C; Mollo A; Zullo F; Insabato L
    Gynecol Oncol; 2021 Feb; 160(2):579-585. PubMed ID: 33276986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas.
    Zhang K; Liu Y; Liu X; Du J; Wang Y; Yang J; Li Y; Liu C
    Pathology; 2021 Feb; 53(2):179-186. PubMed ID: 33070954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of SMARCA4 (BRG1) and SMARCB1 (INI1) in Dedifferentiated Endometrial Carcinoma With Paradoxical Aberrant Expression of MMR in the Well-Differentiated Component: A Case Report and Review of the Literature.
    Kaur R; Mehta J; Borges AM
    Int J Surg Pathol; 2021 Aug; 29(5):571-577. PubMed ID: 32940101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
    Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
    Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of SMARCA4(BRG1) and SMARCB1(INI1) in dedifferentiated and undifferentiated endometrial carcinomas and their correlations with clinicopathological features].
    Bi R; Yu L; Tu XY; Ge HJ; Cheng YF; Chang B; Cai X; Jiang WH; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):590-595. PubMed ID: 31422588
    [No Abstract]   [Full Text] [Related]  

  • 6. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.
    Köbel M; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Stewart CJR; Lee CH
    Am J Surg Pathol; 2018 Jan; 42(1):76-83. PubMed ID: 28863077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
    Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
    Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution.
    Korentzelos D; Elishaev E; Zhao C; Jones MW; Soong TR; Lesnock J; Orellana T; Zeccola A; Diamantopoulos LN; Wald AI; Bhargava R
    Hum Pathol; 2022 Dec; 130():65-78. PubMed ID: 36252860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
    Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
    Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
    J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
    Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
    Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma.
    Stewart CJ; Crook ML
    Pathology; 2015 Aug; 47(5):439-45. PubMed ID: 26126041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
    Espinosa I; Lee CH; D'Angelo E; Palacios J; Prat J
    Am J Surg Pathol; 2017 Aug; 41(8):1121-1128. PubMed ID: 28498284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.